The Europe Autoimmunity Diagnostics Market was valued at $1216 Million in 2025 and projected to reach to $1986 Million by 2030, representing a compound annual growth rate of 8.5%. Europe's autoimmunity diagnostics market is positioned for sustained growth, expanding from $1,216 million in 2025 to $1,986 million by 2030.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe's autoimmunity diagnostics market is valued at $1,216 million in 2025, reflecting the region's significant healthcare investment and high disease prevalence across multiple autoimmune conditions.
With an 8.5% CAGR through 2030, Europe's market growth outpaces the global average of 8.3%, driven by advanced healthcare infrastructure and increasing diagnostic adoption across Western and Central European nations.
Europe's well-established healthcare infrastructure, regulatory frameworks, and reimbursement policies create a favorable environment for innovative autoimmunity diagnostic technologies and market expansion.
Increasing prevalence of autoimmune disorders across Europe, combined with growing awareness and early detection initiatives, is driving demand for advanced diagnostic solutions and testing capabilities.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | AUTOANTIBODIES AND IMMUNOLOGIC TESTS (Test Type) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 8.3% from 2025 to 2030 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 5.57 (2025) |
| Revenue Forecast (Billions) | ~USD 8.29 (2030) |
| Segments Covered | Product, Test Type, Disease Type, Type, End User |
5 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CLINICAL LABORATORIES | 162.8 | 173.7 | 186.8 | 201.9 | 240 | 264.5 | 293.6 | 329.3 | 9.9 |
| HOSPITALS & CLINICS | 108 | 114.2 | 121.6 | 130.3 | 152.1 | 166.2 | 182.9 | 203.3 | 8.9 |
| OTHER END USERS | 37.4 | 39.2 | 41.5 | 44.1 | 50.8 | 55.1 | 60.2 | 66.5 | 8.2 |
| TOTAL | 308.2 | 327.1 | 349.9 | 376.4 | 442.8 | 485.7 | 536.7 | 599 | 9.4 |
| Segment | 2023 | 2024 | 2025 | 2026 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CLINICAL LABORATORIES | 787 | 833 | 888.2 | 952.3 | 1112.8 | 1216 | 1338.5 | 1487.8 | 9 |
| HOSPITALS & CLINICS | 566 | 591.4 | 622.7 | 659.4 | 752 | 812 | 883.3 | 970.5 | 7.7 |
| OTHER END USERS | 208.9 | 215.5 | 224 | 234.1 | 260.1 | 277.2 | 297.7 | 322.9 | 6.3 |
| TOTAL | 1561.9 | 1639.9 | 1734.9 | 1845.9 | 2124.9 | 2305.3 | 2519.5 | 2781.2 | 8.2 |
| Country | 2025 size (native) |
|---|---|
| UK | USD 942.3 Million |
| Germany | USD 684.8 Million |
| France | USD 131.7 Million |
| Italy | USD 153.6 Million |
| Spain | USD 103.4 Million |
| Rest Of Europe | USD 445.5 Million |
Europe's autoimmunity diagnostics market is valued at $1,216 million in 2025 and is projected to reach $1,986 million by 2030.
Europe's autoimmunity diagnostics market is expected to grow at a compound annual growth rate (CAGR) of 8.5% from 2025 to 2030.
Key drivers include Europe's advanced healthcare infrastructure, rising prevalence of autoimmune disorders, aging populations, improved disease awareness, and increasing adoption of innovative diagnostic technologies.
Europe is seeing increased adoption of multiplex assays, point-of-care testing, digital health-integrated diagnostics, and advanced serological testing platforms.
Europe's 8.5% CAGR slightly exceeds the global average of 8.3%, reflecting the region's strong healthcare investment and diagnostic infrastructure.
The study involved estimating activities to determine the current size of the autoimmunity diagnostics market. Exhaustive secondary research was done to collect information on the autoimmunity diagnostics industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the autoimmunity diagnostics market.
Various sources were utilized to gather information for this study in the secondary research process. These sources included company annual reports, press releases, and investor presentations; white papers; certified publications; articles by recognized authors; reputable websites; and information from regulatory bodies and databases, such as D&B Hoovers, Bloomberg Business, and Factiva.
In the primary research process, various sources from both the supply & demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| Abbott Laboratories (US) | Product Specialist |
| Thermo Fisher Scientific Inc. (US) | Clinical Sales Specialist |
Both top-down and bottom-up approaches were used to estimate and validate the autoimmunity diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The research methodology used to estimate the market size includes the following:

The total market was split into several segments after arriving at the overall market size by applying the abovementioned process. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Autoimmune diseases are defined as a medical condition in which an individual's immune system produces antibodies that attack the body's normal tissues. autoimmunity diagnostics systematically identifies autoimmune disorders through clinical assessment and laboratory investigations to detect immune system dysfunction. This process typically involves routine laboratory testing, measurement of systemic inflammatory markers, detection of disease-specific autoantibodies, urinalysis, and other specialized immunologic assays.
Full forecast, segment splits, and company analysis for all Autoimmunity Diagnostics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report